论文部分内容阅读
目的:研究在急性脑梗死的治疗中联合应用丁苯酞、依达拉奉以及纤溶酶的实际疗效。方法:选择2015年6至2015年12月本院收治的急性脑梗死60例进行对照研究,结合随机表法将其平均列入对照组和观察组,对照组使用依达拉奉和纤溶酶进行治疗,观察组在对照组基础上加用丁苯酞。对比两组患者的实际疗效。结果:治疗后,两组治疗有效率、神经功能缺损评分和日常生活能力评分比较,差异具有统计学意义(P<0.05);两组均未发现肝肾损害等严重不良反应。结论:在急性脑梗死患者的治疗中,联合应用丁苯酞、依达拉奉以及纤溶酶的实际疗效显著,且安全性好。
OBJECTIVE: To study the efficacy of combination of butylphthalide, edaravone and plasmin in the treatment of acute cerebral infarction. Methods: Sixty patients with acute cerebral infarction admitted to our hospital from June 2015 to December 2015 were selected and compared with those of the control group and the observation group randomly. The control group was treated with edaravone and plasmin The patients in the observation group were given butylphthalide on the basis of the control group. Compare the actual efficacy of two groups of patients. Results: After treatment, the difference between the two groups in the treatment efficiency, neurological deficit score and daily living ability score was statistically significant (P <0.05). No serious adverse reactions such as liver and kidney damage were found in both groups. Conclusion: In the treatment of patients with acute cerebral infarction, the combination of butylphthalide, edaravone and plasmin has significant therapeutic effect and good safety.